Hutchmed China Limited — Sovleplenib Granted FDA Orphan Drug Designation

(LSE:HCM) HUTCHMED (China) Limited announced that sovleplenib has been granted FDA Orphan Drug Designation (ODD) for the treatment of autoimmune hemolytic anemia (AIHA). This is the second US ODD for sovleplenib, following the October 2026 designation for primary immune thrombocytopenia (ITP). The ODD makes sovleplenib eligible for incentives including 7 years of US market exclusivity, tax credits, and user fee waivers. New Drug Applications (NDAs) for sovleplenib in primary ITP and warm AIHA are currently under review by the National Medical Products Administration (NMPA) in China. The NDA reviews are supported by positive pivotal data from the ESLIM-01 and ESLIM-02 studies. The incidence of AIHA is reported as 0.8–3.0 per 100,000 people per year. The prevalence of AIHA is approximately 17 per 100,000 people. The death rate for AIHA is cited as 8–11%. Warm AIHA comprises approximately 75–80% of adult AIHA cases. The high proportion of warm AIHA among adult cases is noted as potentially increasing the commercial value of sovleplenib. Sovleplenib's ODD for AIHA follows its previous ODD for primary ITP in the US. The company highlights the regulatory incentives associated with ODD status. The ESLIM-01 and ESLIM-02 studies provided the pivotal data supporting the NDAs. The announcement emphasizes the significance of the FDA's ODD decision for sovleplenib's development and commercialization pathway. The company is pursuing regulatory approval for sovleplenib in both primary ITP and warm AIHA indications. The ODD status is expected to facilitate the drug's development and market access in the US. The company notes the potential commercial impact due to the prevalence and mortality rates of AIHA.